1. Moake, JL . Thrombotic microangiopathies. N Engl J Med 2002; 347: 589–600.
Google Scholar | Crossref | Medline | ISI2. Lian, EC . Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost 2005; 31: 625–632.
Google Scholar | Crossref | Medline3. George, JN, Nester, CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 654–666.
Google Scholar | Crossref | Medline | ISI4. Tsai, HM . Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91: 1–19.
Google Scholar | Crossref | Medline | ISI5. Wynick, C, Britto, J, Sawler, D, et al. Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada. Thromb Res 2020; 196: 335–339.
Google Scholar | Crossref | Medline6. Bellmunt, J, De Wit, R, Vaughn, DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376-11: 1015–1026.
Google Scholar | Crossref7. Postow, MA, Sidlow, R, Hellmann, MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378-2: 158–168.
Google Scholar | Crossref8. Gnanapandithan, K, Kharel, P, Grimshaw, A, et al. Hematologic immune-related adverse events from immune checkpoint inhibitors: a systematic review of case-reports and case-series. Blood 2019; 134: 3606.
Google Scholar | Crossref9. McDermott, J, Jimeno, A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc) 2015; 51: 7–20.
Google Scholar | Crossref | Medline10. Khan, Z, Hammer, C, Guardino, E, et al. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach. Genome Med 2019; 11: 39.
Google Scholar | Crossref | Medline11. King, J, de la Cruz, J, Lutzky, J. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). J Immunother Cancer 2017; 5: 19.
Google Scholar | Crossref | Medline12. Honjo, O, Kubo, T, Sugaya, F, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer 2019; 7.
Google Scholar | Crossref | Medline13. Youssef, A, Kasso, N, Torloni, AS, et al. Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol 2018; 2018: 2464619.
Google Scholar | Medline14. Lafranchi, A, Springe, D, Rupp, A, et al. Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma. CEN Case Rep 2020.
Google Scholar | Crossref | Medline15. Hayata, M, Shimanuki, M, Ko, T, et al. Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review. Renal Replacement Therapy 2020; 6. 10.1186/s41100-020-00278-9.
Google Scholar | Crossref16. Reese, JA, Bougie, DW, Curtis, BR, et al. Drug-induced thrombotic microangiopathy: experience of the oklahoma registry and the BloodCenter of wisconsin. Am J Hematol 2015; 90: 406–410.
Google Scholar | Crossref | Medline17. Das, S, Johnson, DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019; 7: 306.
Google Scholar | Crossref | Medline18. Chang, JC, Naqvi, T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist 2003; 8: 375–380.
Google Scholar | Crossref | Medline19. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245. PMID 7249508.
Google Scholar | Crossref | Medline | ISI